Search Results
39 results
Your search is now limited to «Leukemia» expert search.
Healio News 04/25/2019 10:00
Phase 1, first-in-human, open-label, dose-finding study of UCART123 administered intravenously to patients with acute myeloid leukemia, followed by a dose-escalation phase in patients with relapsed or refractory AML and a dose-expansion phase in patients with relapsed or refractory AML, and in poor-prognosis, newly diagnosed patients with AML patients in the European Leukemia Net adverse genetic risk group.
Business Wire 04/24/2019 04:39
GLASGOW, Scotland--(BUSINESS WIRE)--TC BioPharm (TCB), a developer of allogeneic CAR-T immuno-oncology products, and leaders in Gamma Delta T (GDT) cell therapies, today announced it has initiated a Phase I clinical study of TCB002, an allogeneic cell therapy consisting of activated and expanded gamma delta T cells.

Financial Services

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Political Entities

Sources

Strategic Scenarios

Trends

Hints:

  • Actions
    • Bookmark and Share: Allows you to Bookmark the page for easy future retrieval and sharing with colleagues
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Save" button to the right of the search box. 

Click here for more info on Search Results.